Clinical trial of Inofer has started

The clinical study for the iron tablets Inofer, which Drugsson AB (subsidiary of Double Bond Pharmaceutical) has the rights for in Sweden, Norway, Denmark and Finland has now begun. A clinical trial of Inofer was approved, as previously reported, by the Swedish Medical Products Agency and the Ethical Vetting Board on June 20th and yesterday, 4thof September, the first patient received treatment with Inofer tablets. The study is conducted at Skellefteå lasarett and is headed by chief physician Kurt Boman, senior professor at Umeå University.

“We hope the study will proceede as planned and look forward to receiving results that show that Inofer gives an increase in iron levels in heart failure patients.” – comments Igor Lokot, CEO of Double Bond Pharmaceutical and Drugsson AB.

More about iron deficiency and heart failure

About 15% of the world’s population is suffering from iron deficiency. About 250,000 people in Sweden have symptomatic heart failure and half of them have iron deficiency at the same time. This combination of diagnoses leads to increased symptoms and often to hospitalizations. Treatment with common iron tablets does not work due to insufficient intestinal uptake. Therefore, in order to treat iron deficiency in heart failure patients, iron-containing drugs must currently be injected intravenously in a healthcare facility, which is resource-intensive. If it appears that ferrous succinate tablets can treat iron deficiency in heart failure patients, it would be a significant benefit for patients and for the health care, as treatment may be performed at home.

More about Drugsson AB

Contact information

Full Company Name:  

Double Bond Pharmaceutical International AB (publ)

Corporate identity:      


Stock short name:      


Share ISIN code:        


For more info, contact
Igor Lokot, CEO




Follow us on:

LinkedIn, Facebook and Twitter

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

Share this post